Skip to main content
TELO
NASDAQ Life Sciences

Telomir-1 Demonstrates Broad Tumor Cell Mortality in Triple-Negative Breast Cancer Models

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$1.119
Mkt Cap
$37.475M
52W Low
$1.05
52W High
$5.4
52W Position info
6.6% above low
Off High info
79% below high
Rel. Volume info
0.2× avg
Market data snapshot near publication time

TELO is trading near its 52-week low of $1.05 (6.6% above the low) on light trading volume (0.2× avg).

Summary

Telomir Pharmaceuticals reported new preclinical data showing its lead compound, Telomir-1, effectively kills triple-negative breast cancer cells across multiple models, with a confirmed iron-dependent mechanism, and reiterated plans for an IND submission in Q1 2026.


Key Events · Product Development and Regulatory · TELO

  • Strong Preclinical Efficacy in TNBC

    Telomir-1 (Telomir-Zn) demonstrated near-complete tumor cell mortality in MDA-MB-468 human triple-negative breast cancer cells and significant partial reductions in HCC70 and MDA-MB-231 models.

  • Mechanistic Confirmation

    Iron-rescue experiments confirmed that Telomir-Zn's tumor cell mortality is driven by an iron-dependent mechanism, supporting its previously disclosed intracellular metal-modulating activity.

  • IND Application on Track

    The company is completing additional TNBC subtype evaluations, preparing a TNBC mouse xenograft study, and continues IND-enabling activities, anticipating an Investigational New Drug (IND) application submission in the first quarter of 2026.


Analysis · TELO · Life Sciences

Telomir Pharmaceuticals announced compelling preclinical in vitro data for its lead compound, Telomir-1 (Telomir-Zn), showing significant efficacy against human triple-negative breast cancer (TNBC) cell lines. The data indicates near-complete tumor cell mortality in one aggressive TNBC model (MDA-MB-468) and significant reductions in others. The confirmation of an iron-dependent mechanism of action is crucial, suggesting a targeted approach rather than non-specific toxicity. This positive development is particularly important for a micro-cap biotech company like Telomir, providing a strong scientific foundation for its lead candidate. The reiteration of an Investigational New Drug (IND) application submission in Q1 2026 provides a clear near-term catalyst, building on previous positive preclinical announcements and offering a positive counter-narrative amidst recent corporate governance challenges, including a Nasdaq non-compliance notice and a pending reverse merger.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, TELO was trading at $1.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $37.5M. The 52-week trading range was $1.05 to $5.40. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

TELO - Latest Insights

TELO
Nov 06, 2026, 4:41 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.740
Real-time Price: $0.4725 info
Change: -$0.2675 (-36%) info
Market Cap: $34.812M info
TELO
Oct 27, 2026, 4:30 PM EDT
Filing Type: S-3
Importance Score:
7
Price at Filing: $1.02
Real-time Price: $0.4725 info
Change: -$0.5475 (-54%) info
Market Cap: $34.812M info
TELO
Oct 06, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.24
Real-time Price: $0.4725 info
Change: -$0.7675 (-62%) info
Market Cap: $34.812M info
TELO
Oct 06, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.28
Real-time Price: $0.4725 info
Change: -$0.8075 (-63%) info
Market Cap: $34.812M info
TELO
Aug 13, 2026, 5:10 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $1.05
Real-time Price: $0.4725 info
Change: -$0.5775 (-55%) info
Market Cap: $34.812M info